Welcome to our dedicated page for Rapid Micro Biosystems SEC filings (Ticker: RPID), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Rapid Micro Biosystems, Inc. (NASDAQ: RPID) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures filed with the U.S. Securities and Exchange Commission. As an emerging growth company listed on Nasdaq, Rapid Micro Biosystems reports material events, financial results, and financing arrangements through forms such as Form 8-K, as well as its periodic reports on Forms 10-Q and 10-K.
Recent 8-K filings referenced in company communications include results of operations and financial condition for specific quarters and details of a Loan and Security Agreement with Trinity Capital Inc. These filings describe a five-year, $45 million term loan facility, the structure of tranches, interest terms, security interests in company assets, warrant issuance to lenders, and customary covenants and events of default. Other 8-K items incorporate press releases announcing quarterly financial results, including product revenue, service revenue, recurring revenue, and system placement and validation activity.
Through this page, users can review quarterly reports (Form 10-Q), which typically contain more detailed financial statements, segment information, and risk factor updates, and annual reports (Form 10-K), which provide a comprehensive overview of the company’s business, including its Growth Direct system, microbial quality control focus, and role in pharmaceutical manufacturing quality control. Filings related to debt facilities, warrant issuance, and other securities transactions are also accessible.
Stock Titan enhances these documents with AI-powered summaries that highlight key points from lengthy filings, helping readers quickly understand topics such as revenue composition, recurring revenue trends, capital structure changes, covenant terms, and material events. Users interested in Rapid Micro Biosystems’ regulatory history, financial condition, and obligations under its loan facility can use this page to follow new filings as they are made available through EDGAR.
RAPID MICRO BIOSYSTEMS, INC. chief operating officer John J. Addington reported an automatic sale of 9,603 shares of Class A common stock at an average price of
After this transaction, he directly holds 316,762 shares of Class A common stock, indicating the sale represents a small portion of his overall position and is tied to routine equity-compensation tax withholding rather than discretionary selling.
RAPID MICRO BIOSYSTEMS, INC.
RAPID MICRO BIOSYSTEMS, INC. president and CEO Robert G. Spignesi Jr. reported an automatic sale of 17,922 shares of Class A common stock at $4.1115 per share on March 10, 2026.
The footnote explains this sale was made solely to cover tax obligations related to the vesting of restricted stock units. After the transaction, he directly owned 1,169,848 shares, indicating this was a small, routine disposition relative to his overall stake.
Rapid Micro Biosystems filed its annual report describing a business focused on automating microbial quality control in pharmaceutical manufacturing through its Growth Direct platform. The system replaces manual plate handling and visual colony counting with robotic automation, optical imaging and vision algorithms, targeting faster, more accurate and data-secure testing.
The company reports a large addressable market, estimating approximately $5.0 billion for system sales and a further $5.0 billion for recurring consumables and services. As of December 31, 2025, it had incurred an accumulated deficit of $522.4 million, including a net loss of $47.1 million for 2025 versus $46.9 million for 2024.
Rapid Micro Biosystems highlights positive gross margins in 2025 after prior investments in manufacturing and service infrastructure, but warns it may continue to incur losses and may need additional capital. It emphasizes growth initiatives around biologics and cell and gene therapies, a new rapid sterility test, integration with Lonza’s MODA-EM module, and a global distribution and collaboration agreement with MilliporeSigma that includes minimum system purchase commitments and potential supply-chain cost savings.
Rapid Micro Biosystems reported record 2025 results with continued losses but improving scale. Total revenue reached $33.6 million in 2025, up 20% from 2024, with fourth quarter revenue of $11.3 million, a 37% increase year over year. Product revenue grew to $23.4 million for the year, while recurring revenue rose to $17.8 million.
Full-year gross margin improved to 3% from 0% in 2024, or 6% on a non-GAAP basis excluding a write-off of unusable inventory and related warranty expense. Net loss was $47.1 million, similar to $46.9 million in 2024, as operating expenses fell 3% to $48.4 million.
The company highlighted record multi-system orders from Amgen in late 2025 and a follow-on multi-system order from Samsung Biologics in early 2026, underscoring broader adoption of its Growth Direct platform. For 2026, it expects total revenue of $37.0 million to $41.0 million, 30 to 38 Growth Direct system placements and gross margin of approximately 20%.
Sean M. Wirtjes reported sales of Class A shares and a planned sale tied to restricted stock vesting. The filing shows sale of 6,027 Class A shares on
RPID submitted a Rule 144 notice proposing the sale of 9,603 Class A shares through Fidelity Brokerage Services LLC. The shares were recorded as restricted stock vesting on
Robert G. Spignesi filed a Form 144 notifying a proposed sale of 17,922 Class A shares arising from restricted stock vesting on
The notice also reports prior sales of 12,840 Class A shares on
RAPID MICRO BIOSYSTEMS, INC. director Natale S. Ricciardi exercised a stock option and acquired Class A common shares. On February 27, 2026, he exercised an option for 842 shares at an exercise price of $0.75 per share. Following the exercise, his direct holdings of Class A common stock increased to 29,442 shares. The footnote indicates the option was already fully vested and exercisable, meaning this transaction reflects the use of an existing equity award rather than a new grant or open-market purchase.
RAPID MICRO BIOSYSTEMS, INC. chief operating officer John J. Wilson reported an automatic sale of 5,403 shares of Class A common stock at $3.923 per share. According to the footnote, this sale was made solely to cover tax obligations tied to vesting restricted stock units. After the transaction, he directly held 326,365 shares of Class A common stock.